Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773) - Total Liabilities
Based on the latest financial reports, Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773) has total liabilities worth CN¥719.98 Million CNY (≈ $105.36 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 002773 operating cash flow to assess how effectively this company generates cash.
Chengdu Kanghong Pharmaceuticals Group Co Ltd - Total Liabilities Trend (2009–2024)
This chart illustrates how Chengdu Kanghong Pharmaceuticals Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Chengdu Kanghong Pharmaceuticals Group C to evaluate the company's liquid asset resilience ratio.
Chengdu Kanghong Pharmaceuticals Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Chengdu Kanghong Pharmaceuticals Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Huber+suhner AG
SW:HUBN
|
Switzerland | CHF199.76 Million |
|
China Petroleum Engineering Corp
SHG:600339
|
China | CN¥97.35 Billion |
|
Autel Intelligent Technology Corp Ltd
SHG:688208
|
China | CN¥3.65 Billion |
|
Amedisys Inc
NASDAQ:AMED
|
USA | $940.48 Million |
|
Liquidia Technologies Inc
NASDAQ:LQDA
|
USA | $253.93 Million |
|
Trigano S.A.
PA:TRI
|
France | €1.19 Billion |
|
CI Financial Corp
TO:CIX
|
Canada | CA$10.53 Billion |
|
WesBanco Inc
NASDAQ:WSBC
|
USA | $23.66 Billion |
Liability Composition Analysis (2009–2024)
This chart breaks down Chengdu Kanghong Pharmaceuticals Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 002773 market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chengdu Kanghong Pharmaceuticals Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chengdu Kanghong Pharmaceuticals Group Co Ltd (2009–2024)
The table below shows the annual total liabilities of Chengdu Kanghong Pharmaceuticals Group Co Ltd from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥695.07 Million ≈ $101.71 Million |
-3.16% |
| 2023-12-31 | CN¥717.76 Million ≈ $105.03 Million |
-11.81% |
| 2022-12-31 | CN¥813.85 Million ≈ $119.09 Million |
-4.37% |
| 2021-12-31 | CN¥851.08 Million ≈ $124.54 Million |
-31.66% |
| 2020-12-31 | CN¥1.25 Billion ≈ $182.23 Million |
+3.22% |
| 2019-12-31 | CN¥1.21 Billion ≈ $176.54 Million |
+8.60% |
| 2018-12-31 | CN¥1.11 Billion ≈ $162.56 Million |
+6.54% |
| 2017-12-31 | CN¥1.04 Billion ≈ $152.58 Million |
+22.20% |
| 2016-12-31 | CN¥853.27 Million ≈ $124.86 Million |
+126.82% |
| 2015-12-31 | CN¥376.19 Million ≈ $55.05 Million |
+14.30% |
| 2014-12-31 | CN¥329.11 Million ≈ $48.16 Million |
+7.66% |
| 2013-12-31 | CN¥305.69 Million ≈ $44.73 Million |
-18.57% |
| 2012-12-31 | CN¥375.39 Million ≈ $54.93 Million |
+4.39% |
| 2011-12-31 | CN¥359.58 Million ≈ $52.62 Million |
-1.81% |
| 2010-12-31 | CN¥366.21 Million ≈ $53.59 Million |
+29.07% |
| 2009-12-31 | CN¥283.73 Million ≈ $41.52 Million |
-- |
About Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chengdu Kanghong Pharmaceutical Group Co., Ltd engages in the research, development, manufacture, and distribution of medicine for ophthalmic, neuropsychiatric and other applications in China. It also develops a pipeline of clinical and pre-clinical programs for ophthalmology, CNS, oncology, and common disease. The company was founded in 1996 and is based in Chengdu, China.